Trial Profile
A Cohort (Follow Up) Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax (Tablet) Post Discharge for Ten Days, Without the Need for Routine Coagulation Monitoring and Dose Adjustment
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions
- 27 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Apr 2009 New trial record